Pharmacokinetics and systems pharmacology of monoclonal antibody olaratumab for inoperable soft tissue sarcoma
作者: Sujit NairAkshay IyerVishnu VijaySairam BandlamudiAdrián Llerena
作者单位: 1Amrita Vishwa Vidyapeetham University
2Amrita Cancer Discovery Biology Laboratory, Amrita Vishwa Vidyapeetham University, Amritapuri, Kerala, India
3Corporate and Industry Relations (CIR), Amrita Vishwa Vidyapeetham University, Amritapuri, Kerala, India
4CICAB Clinical Research Centre at Extremadura University Hospital and Medical School, Universidad de Extremadura, Badajoz, Spain
刊名: Advances in Modern Oncology Research, 2017, Vol.3 (3), pp.114-125
来源数据库: Directory of Open Access Journals
DOI: 10.18282/amor.v3.i3.194
关键词: OlaratumabOrphan drugCancerSarcomaPDGFRMonoclonal antibodyPharmacokineticsPharmacologyPrecision medicineFinancial toxicity
原始语种摘要: Olaratumab, a human IgG1 monoclonal antibody, has received accelerated approval from the US Food and Drug Administration (FDA), and conditional marketing authorization by the European Medicines Agency’s (EMA) accelerated assessment program, for metastatic soft tissue sarcoma. This is a heterogeneous group of diseases with several subtypes, and the current standard of care since the past few decades has been primarily doxorubicin. Olaratumab is an antagonist of platelet-derived growth factor receptor alpha (PDGFR alpha) that prevents the binding of PDGF ligands to this receptor, consequently inhibiting subsequent dimerization of the receptor and downstream signal transduction, thereby inhibiting carcinogenesis. In Phase 1 and Phase 2 clinical trials, olaratumab demonstrated acceptable...
全文获取路径: PDF下载  DOAJ  (合作)

  • antibody 抗体
  • monoclonal 单细胞系的
  • inoperable 不能手术的
  • sarcoma 肉瘤
  • pharmacology 药理学
  • immunogenicity 致免疫性
  • receptor 接受体
  • medicine 
  • tissue 组织
  • doxorubicin 阿霉素